
Immix Biopharma (IMMX) Stock Forecast & Price Target
Immix Biopharma (IMMX) Analyst Ratings
Bulls say
Immix Biopharma is supported by a compelling clinical thesis, as NXC-201 has shown an 89% complete response rate across 45 patients, with 100% cardiac responses and 92% organ responses among evaluable patients, while safety remains manageable with no relapses reported and no new grade ≥3 CRS, ICANS, or high-grade cardiac events. The company’s near-term value is further reinforced by visible regulatory and commercial catalysts, including a data update from the NEXICART-2 trial, planned BLA submission to the FDA in 1H27 or mid-2027, Phase 3 initiation in 1H:27 or 2H27, and a potential U.S. launch in r/r AL amyloidosis in 2028. Financially, Immix ended 2Q26 with ~$234.2M in cash and 3Q26 with ~$340.9M, implying runway into mid-2028, while disciplined expense control and rising conviction in accelerated approval support the positive outlook.
Bears say
Immix Biopharma is viewed pessimistically because its lead CAR-T candidate NXC-201 faces meaningful clinical risk, including potential safety problems such as Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome, with no assurance of a tolerable profile or success in the clinic. Regulatory risk is also elevated because none of its drugs have been approved by the FDA, filing dates could slip, and evolving requirements may delay development and approval, while competition from multiple CAR-T and bispecific T-cell engager programs could further pressure differentiation. Commercially and financially, high CAR-T costs may limit payer reimbursement and market access, production may not meet demand, and the company is likely to need additional capital for commercial trials and launch without certainty of favorable financing.
This aggregate rating is based on analysts' research of Immix Biopharma and is not a guaranteed prediction by Public.com or investment advice.
Immix Biopharma (IMMX) Analyst Forecast & Price Prediction
Start investing in Immix Biopharma (IMMX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Immix Biopharma (IMMX) Forecast
Immix Biopharma (IMMX) Analyst Forecast & Price Prediction
Start investing in Immix Biopharma (IMMX)
Order type
Buy in
Order amount
Est. shares
0 shares